I
IMMUNOVANT INC
NASDAQ: IMVT (Immunovant, Inc.)
Last update: 15 hours ago18.94
0.20 (1.07%)
| Previous Close | 18.74 |
| Open | 18.83 |
| Volume | 833,519 |
| Avg. Volume (3M) | 1,560,739 |
| Market Cap | 3,301,561,088 |
| Price / Book | 4.79 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -2.73 |
| Total Debt/Equity (MRQ) | 0.01% |
| Current Ratio (MRQ) | 11.16 |
| Operating Cash Flow (TTM) | -375.87 M |
| Levered Free Cash Flow (TTM) | -227.82 M |
| Return on Assets (TTM) | -37.97% |
| Return on Equity (TTM) | -62.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Immunovant, Inc. | Bearish | Bearish |
AIStockmoo Score
0.3
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.25 |
|
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 58.17% |
| % Held by Institutions | 55.78% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Baker Bros. Advisors Lp | 30 Jun 2025 | 5,457,881 |
| Armistice Capital, Llc | 30 Jun 2025 | 5,200,000 |
| Alpine Global Management, Llc | 30 Jun 2025 | 2,626,692 |
| Two Seas Capital Lp | 30 Jun 2025 | 2,252,772 |
| Perceptive Advisors Llc | 30 Jun 2025 | 2,137,890 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (HC Wainwright & Co., 84.79%) | Buy |
| Median | 30.00 (58.40%) | |
| Low | 16.00 (Truist Securities, -15.52%) | Hold |
| Average | 26.40 (39.39%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 16.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 14 Oct 2025 | 16.00 (-15.52%) | Hold | 17.49 |
| JP Morgan | 30 Sep 2025 | 33.00 (74.23%) | Buy | 16.12 |
| 12 Aug 2025 | 37.00 (95.35%) | Buy | 15.21 | |
| HC Wainwright & Co. | 04 Sep 2025 | 35.00 (84.79%) | Buy | 16.12 |
| B of A Securities | 12 Aug 2025 | 30.00 (58.39%) | Buy | 15.21 |
| UBS | 28 Jul 2025 | 18.00 (-4.96%) | Hold | 16.76 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Sep 2025 | Announcement | Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients |
| 11 Aug 2025 | Announcement | Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |